share_log

Navidea Biopharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent App 17/370,920 Titled "Synthesis Of Uniformly Defined Molecular Weight Mannosylated Dextrans & Derivatives Thereof (For Tilmanocept Immunotherapeutic Applications)"

Navidea Biopharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent App 17/370,920 Titled "Synthesis Of Uniformly Defined Molecular Weight Mannosylated Dextrans & Derivatives Thereof (For Tilmanocept Immunotherapeutic Applications)"

Navidea Biopharmaceuticals已收到其美国专利应用程序17/370,920的许可通知,标题为 “统一定义的分子量甘露糖化葡聚糖及其衍生物的合成(用于Tilmanocept免疫疗法应用)”
Benzinga ·  2023/05/24 15:58

Navidea Biopharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent App 17/370,920 Titled "Synthesis Of Uniformly Defined Molecular Weight Mannosylated Dextrans & Derivatives Thereof (For Tilmanocept Immunotherapeutic Applications)"

Navidea Biopharmaceuticals已收到其美国专利应用程序17/370,920的许可通知,标题为 “统一定义的分子量甘露糖化葡聚糖及其衍生物的合成(用于Tilmanocept免疫疗法应用)”

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发